23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design, synthesis, and SAR of tachykinin antagonists: modulation of balance in NK(1)/NK(2) receptor antagonist activity.
Astrazeneca Pharmaceuticals
4-Piperidin-4-ylidenemethyl-benzamides asd-opioid receptor agonists for CNS indications: identifying clinical candidates.
Astrazeneca Pharmaceuticals
Multiparameter exploration of piperazine derivatives asd-opioid receptor agonists for CNS indications.
Astrazeneca Pharmaceuticals
2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.
Astrazeneca Pharmaceuticals
Synthesis and SAR of sulfoxide substituted carboxyquinolines as NK3 receptor antagonists.
Astrazeneca Pharmaceuticals
Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).
Astrazeneca Pharmaceuticals
Developing dual functional allosteric modulators of GABA(A) receptors.
Astrazeneca Pharmaceuticals
4-aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators.
Astrazeneca Pharmaceuticals
Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1.
Astrazeneca Pharmaceuticals
SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2.
Astrazeneca Pharmaceuticals
De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
Astrazeneca Pharmaceuticals
The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing.
Astrazeneca Pharmaceuticals
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Astrazeneca Pharmaceuticals
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Astrazeneca Pharmaceuticals
Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency.
Astrazeneca Pharmaceuticals
Synthesis of novel quinolone and quinoline-2-carboxylic acid (4-morpholin-4-yl-phenyl)amides: a late-stage diversification approach to potent 5HT1B antagonists.
Astrazeneca Pharmaceuticals
Structural analysis and optimization of NK(1) receptor antagonists through modulation of atropisomer interconversion properties.
Astrazeneca Pharmaceuticals
Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.
Astrazeneca Pharmaceuticals
Potent reversible inhibitors of the protein tyrosine phosphatase CD45.
Astrazeneca Pharmaceuticals
The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1.
Astrazeneca Pharmaceuticals
Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity
University of North Carolina At Chapel Hill